Cite

HARVARD Citation

    Mrak, D. et al. (2022). Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Annals of the rheumatic diseases. 81 (12), pp. 1750-1756. [Online]. 
  
Back to record